Search

Your search keyword '"Oksanen, Minna"' showing total 245 results
Start Over Author "Oksanen, Minna"
245 results on '"Oksanen, Minna"'

1. Pulmonary hypertension in Finland 2008-2020: A descriptive real-world cohort study (FINPAH)

Author

Harju, Terttu, Heliövaara, Elina, Jääskeläinen, Pertti, Kahlos, Katriina, Korhonen, Pentti, Kyllönen, Tiina, Leskelä, Pauliina, Majamaa-Voltti, Kirsi, Simonen, Piia, Turpeinen, Anu, Tuunanen, Helena, Vepsäläinen, Ville, Vihinen, Tapani, Pentikäinen, Markku, Asseburg, Christian, Oksanen, Minna, Soini, Erkki, Wennerström, Christina, and Puhakka, Airi

Published
2025
Full Text
View/download PDF

5. Risk-stratified analysis of long-term clinical outcomes and cumulative costs in Finnish patients with recent acute coronary syndrome or coronary revascularization: A 5-year real-world study using electronic health records

Author

Interne Geneeskunde Vasculaire, Circulatory Health, Oksanen, Minna, Parviainen, Jenna, Asseburg, Christian, Hageman, Steven, Rissanen, Tuomas T., Kivelä, Annukka, Taipale, Kristian, Visseren, Frank, Martikainen, Janne, Interne Geneeskunde Vasculaire, Circulatory Health, Oksanen, Minna, Parviainen, Jenna, Asseburg, Christian, Hageman, Steven, Rissanen, Tuomas T., Kivelä, Annukka, Taipale, Kristian, Visseren, Frank, and Martikainen, Janne

Published
2024

6. PSEN1ΔE9, APPswe, and APOE4 Confer Disparate Phenotypes in Human iPSC-Derived Microglia

Author

Konttinen, Henna, Cabral-da-Silva, Mauricio e Castro, Ohtonen, Sohvi, Wojciechowski, Sara, Shakirzyanova, Anastasia, Caligola, Simone, Giugno, Rosalba, Ishchenko, Yevheniia, Hernández, Damián, Fazaludeen, Mohammad Feroze, Eamen, Shaila, Budia, Mireia Gómez, Fagerlund, Ilkka, Scoyni, Flavia, Korhonen, Paula, Huber, Nadine, Haapasalo, Annakaisa, Hewitt, Alex W., Vickers, James, Smith, Grady C., Oksanen, Minna, Graff, Caroline, Kanninen, Katja M., Lehtonen, Sarka, Propson, Nicholas, Schwartz, Michael P., Pébay, Alice, Koistinaho, Jari, Ooi, Lezanne, and Malm, Tarja

Published
2019
Full Text
View/download PDF

7. Risk-stratified analysis of long-term clinical outcomes and cumulative costs in Finnish patients with recent acute coronary syndrome or coronary revascularization: a 5-year real-world study using electronic health records.

Author

Oksanen, Minna, Parviainen, Jenna, Asseburg, Christian, Hageman, Steven, Rissanen, Tuomas T, Kivelä, Annukka, Taipale, Kristian, Visseren, Frank, and Martikainen, Janne

Subjects
ACUTE coronary syndrome, ELECTRONIC health records, CORONARY artery bypass, DISEASE risk factors, CORONARY artery surgery
Abstract

Aims Risk assessment is essential in the prevention of cardiovascular disease. In patients with recent acute coronary syndrome (ACS) or coronary revascularization, risk prediction tools, like the European Society of Cardiology guideline recommended SMART-REACH risk score, are increasingly used to predict the risk of recurrent cardiovascular events enabling risk-based personalized prevention. However, little is known about the association between risk stratification and the social and healthcare costs at a population level. This study evaluated the associations between baseline SMART-REACH risk scores, long-term recurrent clinical events, cumulative costs, and post-index event LDL-C goal attainment in patients with recent ACS and/or revascularization. Methods and results This retrospective study used electronic health records and was conducted in the North Karelia region of Finland. The study cohort included all patients aged 45–85 admitted to a hospital for ACS or who underwent percutaneous coronary intervention or coronary artery bypass surgery between 1 January 2017 and 31 December 2021. Patients were divided into quintiles based on their baseline SMART-REACH risk scores to examine the associations between predicted 5-year scores and selected clinical and economic outcomes. In addition, simple age-based stratification was conducted as a sensitivity analysis. The observed 5-year cumulative incidence of recurrent events ranged from 20% in the lowest to 41% in the highest risk quintile, whereas the corresponding predicted risks ranged from 13% to 51%, and cumulative 5-year mean total costs per patient ranged from 15 827 to 46 182€, respectively. Both monitoring and attainment of low LDL-C values were suboptimal. Conclusion The use of the SMART-REACH quintiles as a population-level risk stratification tool successfully stratified patients into subgroups with different cumulative numbers of recurrent events and cumulative total costs. However, more research is needed to define clinically and economically optimal threshold values for a population-level stratification. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. PSEN1 Mutant iPSC-Derived Model Reveals Severe Astrocyte Pathology in Alzheimer's Disease

Author

Oksanen, Minna, Petersen, Andrew J., Naumenko, Nikolay, Puttonen, Katja, Lehtonen, Šárka, Gubert Olivé, Max, Shakirzyanova, Anastasia, Leskelä, Stina, Sarajärvi, Timo, Viitanen, Matti, Rinne, Juha O., Hiltunen, Mikko, Haapasalo, Annakaisa, Giniatullin, Rashid, Tavi, Pasi, Zhang, Su-Chun, Kanninen, Katja M., Hämäläinen, Riikka H., and Koistinaho, Jari

Published
2017
Full Text
View/download PDF

11. Metabolic alterations in Parkinson’s disease astrocytes

Author

Sonninen, Tuuli-Maria, Hämäläinen, Riikka H., Koskuvi, Marja, Oksanen, Minna, Shakirzyanova, Anastasia, Wojciechowski, Sara, Puttonen, Katja, Naumenko, Nikolay, Goldsteins, Gundars, Laham-Karam, Nihay, Lehtonen, Marko, Tavi, Pasi, Koistinaho, Jari, and Lehtonen, Šárka

Published
2020
Full Text
View/download PDF

14. Supplementary Figure S6. NK-cells redistribute towards tumors and draining lymph nodes after treatment with trastuzumab-coding oncolytic virus from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer

Author

Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Guse, Kilian, primary, Gutmann, Theresia, primary, Savola, Paula, primary, Oksanen, Minna, primary, Kanerva, Anna, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure S1. Trastuzumab-coding oncolytic adenovirus mediates cytotoxicity in several HER2-positive and negative cancer cell lines from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer

Author

Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Guse, Kilian, primary, Gutmann, Theresia, primary, Savola, Paula, primary, Oksanen, Minna, primary, Kanerva, Anna, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure S2. Oncolytic adenovirus coding for trastuzumab shows superior cell killing efficacy when dosed according to functional titers from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer

Author

Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Guse, Kilian, primary, Gutmann, Theresia, primary, Savola, Paula, primary, Oksanen, Minna, primary, Kanerva, Anna, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure S4. Oncolytic adenoviruses inhibit tumor growth, while trastuzumab transgene does not add to efficacy against HER2-negative breast cancer in vivo from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer

Author

Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Guse, Kilian, primary, Gutmann, Theresia, primary, Savola, Paula, primary, Oksanen, Minna, primary, Kanerva, Anna, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Kanerva, Anna, primary, Nokisalmi, Petri, primary, Diaconu, Iulia, primary, Koski, Anniina, primary, Cerullo, Vincenzo, primary, Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Oksanen, Minna, primary, Heiskanen, Raita, primary, Pesonen, Saila, primary, Joensuu, Timo, primary, Alanko, Tuomo, primary, Partanen, Kaarina, primary, Laasonen, Leena, primary, Kairemo, Kalevi, primary, Pesonen, Sari, primary, Kangasniemi, Lotta, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure Legend from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Kanerva, Anna, primary, Nokisalmi, Petri, primary, Diaconu, Iulia, primary, Koski, Anniina, primary, Cerullo, Vincenzo, primary, Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Oksanen, Minna, primary, Heiskanen, Raita, primary, Pesonen, Saila, primary, Joensuu, Timo, primary, Alanko, Tuomo, primary, Partanen, Kaarina, primary, Laasonen, Leena, primary, Kairemo, Kalevi, primary, Pesonen, Sari, primary, Kangasniemi, Lotta, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table 3 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Kanerva, Anna, primary, Nokisalmi, Petri, primary, Diaconu, Iulia, primary, Koski, Anniina, primary, Cerullo, Vincenzo, primary, Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Oksanen, Minna, primary, Heiskanen, Raita, primary, Pesonen, Saila, primary, Joensuu, Timo, primary, Alanko, Tuomo, primary, Partanen, Kaarina, primary, Laasonen, Leena, primary, Kairemo, Kalevi, primary, Pesonen, Sari, primary, Kangasniemi, Lotta, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Data from Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors

Author

Nokisalmi, Petri, primary, Pesonen, Sari, primary, Escutenaire, Sophie, primary, Särkioja, Merja, primary, Raki, Mari, primary, Cerullo, Vincenzo, primary, Laasonen, Leena, primary, Alemany, Ramon, primary, Rojas, Juan, primary, Cascallo, Manel, primary, Guse, Kilian, primary, Rajecki, Maria, primary, Kangasniemi, Lotta, primary, Haavisto, Elina, primary, Karioja-Kallio, Aila, primary, Hannuksela, Päivi, primary, Oksanen, Minna, primary, Kanerva, Anna, primary, Joensuu, Timo, primary, Ahtiainen, Laura, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 3 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Kanerva, Anna, primary, Nokisalmi, Petri, primary, Diaconu, Iulia, primary, Koski, Anniina, primary, Cerullo, Vincenzo, primary, Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Oksanen, Minna, primary, Heiskanen, Raita, primary, Pesonen, Saila, primary, Joensuu, Timo, primary, Alanko, Tuomo, primary, Partanen, Kaarina, primary, Laasonen, Leena, primary, Kairemo, Kalevi, primary, Pesonen, Sari, primary, Kangasniemi, Lotta, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Kanerva, Anna, primary, Nokisalmi, Petri, primary, Diaconu, Iulia, primary, Koski, Anniina, primary, Cerullo, Vincenzo, primary, Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Oksanen, Minna, primary, Heiskanen, Raita, primary, Pesonen, Saila, primary, Joensuu, Timo, primary, Alanko, Tuomo, primary, Partanen, Kaarina, primary, Laasonen, Leena, primary, Kairemo, Kalevi, primary, Pesonen, Sari, primary, Kangasniemi, Lotta, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Kanerva, Anna, primary, Nokisalmi, Petri, primary, Diaconu, Iulia, primary, Koski, Anniina, primary, Cerullo, Vincenzo, primary, Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Oksanen, Minna, primary, Heiskanen, Raita, primary, Pesonen, Saila, primary, Joensuu, Timo, primary, Alanko, Tuomo, primary, Partanen, Kaarina, primary, Laasonen, Leena, primary, Kairemo, Kalevi, primary, Pesonen, Sari, primary, Kangasniemi, Lotta, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 4 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Kanerva, Anna, primary, Nokisalmi, Petri, primary, Diaconu, Iulia, primary, Koski, Anniina, primary, Cerullo, Vincenzo, primary, Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Oksanen, Minna, primary, Heiskanen, Raita, primary, Pesonen, Saila, primary, Joensuu, Timo, primary, Alanko, Tuomo, primary, Partanen, Kaarina, primary, Laasonen, Leena, primary, Kairemo, Kalevi, primary, Pesonen, Sari, primary, Kangasniemi, Lotta, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure 5 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Kanerva, Anna, primary, Nokisalmi, Petri, primary, Diaconu, Iulia, primary, Koski, Anniina, primary, Cerullo, Vincenzo, primary, Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Oksanen, Minna, primary, Heiskanen, Raita, primary, Pesonen, Saila, primary, Joensuu, Timo, primary, Alanko, Tuomo, primary, Partanen, Kaarina, primary, Laasonen, Leena, primary, Kairemo, Kalevi, primary, Pesonen, Sari, primary, Kangasniemi, Lotta, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Table 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Kanerva, Anna, primary, Nokisalmi, Petri, primary, Diaconu, Iulia, primary, Koski, Anniina, primary, Cerullo, Vincenzo, primary, Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Oksanen, Minna, primary, Heiskanen, Raita, primary, Pesonen, Saila, primary, Joensuu, Timo, primary, Alanko, Tuomo, primary, Partanen, Kaarina, primary, Laasonen, Leena, primary, Kairemo, Kalevi, primary, Pesonen, Sari, primary, Kangasniemi, Lotta, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Table 1 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Pesonen, Sari, primary, Diaconu, Iulia, primary, Kangasniemi, Lotta, primary, Ranki, Tuuli, primary, Kanerva, Anna, primary, Pesonen, Saila K., primary, Gerdemann, Ulrike, primary, Leen, Ann M., primary, Kairemo, Kalevi, primary, Oksanen, Minna, primary, Haavisto, Elina, primary, Holm, Sirkka-Liisa, primary, Karioja-Kallio, Aila, primary, Kauppinen, Satu, primary, Partanen, Kaarina P. L., primary, Laasonen, Leena, primary, Joensuu, Tima, primary, Alanko, Tuomo, primary, Cerullo, Vincenzo, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table 3 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Pesonen, Sari, primary, Diaconu, Iulia, primary, Kangasniemi, Lotta, primary, Ranki, Tuuli, primary, Kanerva, Anna, primary, Pesonen, Saila K., primary, Gerdemann, Ulrike, primary, Leen, Ann M., primary, Kairemo, Kalevi, primary, Oksanen, Minna, primary, Haavisto, Elina, primary, Holm, Sirkka-Liisa, primary, Karioja-Kallio, Aila, primary, Kauppinen, Satu, primary, Partanen, Kaarina P. L., primary, Laasonen, Leena, primary, Joensuu, Tima, primary, Alanko, Tuomo, primary, Cerullo, Vincenzo, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 2 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Pesonen, Sari, primary, Diaconu, Iulia, primary, Kangasniemi, Lotta, primary, Ranki, Tuuli, primary, Kanerva, Anna, primary, Pesonen, Saila K., primary, Gerdemann, Ulrike, primary, Leen, Ann M., primary, Kairemo, Kalevi, primary, Oksanen, Minna, primary, Haavisto, Elina, primary, Holm, Sirkka-Liisa, primary, Karioja-Kallio, Aila, primary, Kauppinen, Satu, primary, Partanen, Kaarina P. L., primary, Laasonen, Leena, primary, Joensuu, Tima, primary, Alanko, Tuomo, primary, Cerullo, Vincenzo, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

34. Data from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Pesonen, Sari, primary, Diaconu, Iulia, primary, Kangasniemi, Lotta, primary, Ranki, Tuuli, primary, Kanerva, Anna, primary, Pesonen, Saila K., primary, Gerdemann, Ulrike, primary, Leen, Ann M., primary, Kairemo, Kalevi, primary, Oksanen, Minna, primary, Haavisto, Elina, primary, Holm, Sirkka-Liisa, primary, Karioja-Kallio, Aila, primary, Kauppinen, Satu, primary, Partanen, Kaarina P. L., primary, Laasonen, Leena, primary, Joensuu, Tima, primary, Alanko, Tuomo, primary, Cerullo, Vincenzo, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

35. Data from Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients

Author

Cerullo, Vincenzo, primary, Pesonen, Sari, primary, Diaconu, Iulia, primary, Escutenaire, Sophie, primary, Arstila, Petteri T., primary, Ugolini, Matteo, primary, Nokisalmi, Petri, primary, Raki, Mari, primary, Laasonen, Leena, primary, Särkioja, Merja, primary, Rajecki, Maria, primary, Kangasniemi, Lotta, primary, Guse, Kilian, primary, Helminen, Andreas, primary, Ahtiainen, Laura, primary, Ristimäki, Ari, primary, Räisänen-Sokolowski, Anne, primary, Haavisto, Elina, primary, Oksanen, Minna, primary, Karli, Eerika, primary, Karioja-Kallio, Aila, primary, Holm, Sirkka-Liisa, primary, Kouri, Mauri, primary, Joensuu, Timo, primary, Kanerva, Anna, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Table 5 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Pesonen, Sari, primary, Diaconu, Iulia, primary, Kangasniemi, Lotta, primary, Ranki, Tuuli, primary, Kanerva, Anna, primary, Pesonen, Saila K., primary, Gerdemann, Ulrike, primary, Leen, Ann M., primary, Kairemo, Kalevi, primary, Oksanen, Minna, primary, Haavisto, Elina, primary, Holm, Sirkka-Liisa, primary, Karioja-Kallio, Aila, primary, Kauppinen, Satu, primary, Partanen, Kaarina P. L., primary, Laasonen, Leena, primary, Joensuu, Tima, primary, Alanko, Tuomo, primary, Cerullo, Vincenzo, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Table 4 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Pesonen, Sari, primary, Diaconu, Iulia, primary, Kangasniemi, Lotta, primary, Ranki, Tuuli, primary, Kanerva, Anna, primary, Pesonen, Saila K., primary, Gerdemann, Ulrike, primary, Leen, Ann M., primary, Kairemo, Kalevi, primary, Oksanen, Minna, primary, Haavisto, Elina, primary, Holm, Sirkka-Liisa, primary, Karioja-Kallio, Aila, primary, Kauppinen, Satu, primary, Partanen, Kaarina P. L., primary, Laasonen, Leena, primary, Joensuu, Tima, primary, Alanko, Tuomo, primary, Cerullo, Vincenzo, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 3 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Pesonen, Sari, primary, Diaconu, Iulia, primary, Kangasniemi, Lotta, primary, Ranki, Tuuli, primary, Kanerva, Anna, primary, Pesonen, Saila K., primary, Gerdemann, Ulrike, primary, Leen, Ann M., primary, Kairemo, Kalevi, primary, Oksanen, Minna, primary, Haavisto, Elina, primary, Holm, Sirkka-Liisa, primary, Karioja-Kallio, Aila, primary, Kauppinen, Satu, primary, Partanen, Kaarina P. L., primary, Laasonen, Leena, primary, Joensuu, Tima, primary, Alanko, Tuomo, primary, Cerullo, Vincenzo, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Table 2 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Pesonen, Sari, primary, Diaconu, Iulia, primary, Kangasniemi, Lotta, primary, Ranki, Tuuli, primary, Kanerva, Anna, primary, Pesonen, Saila K., primary, Gerdemann, Ulrike, primary, Leen, Ann M., primary, Kairemo, Kalevi, primary, Oksanen, Minna, primary, Haavisto, Elina, primary, Holm, Sirkka-Liisa, primary, Karioja-Kallio, Aila, primary, Kauppinen, Satu, primary, Partanen, Kaarina P. L., primary, Laasonen, Leena, primary, Joensuu, Tima, primary, Alanko, Tuomo, primary, Cerullo, Vincenzo, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figures 1-6, Tables 1-3 from Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients

Author

Cerullo, Vincenzo, primary, Pesonen, Sari, primary, Diaconu, Iulia, primary, Escutenaire, Sophie, primary, Arstila, Petteri T., primary, Ugolini, Matteo, primary, Nokisalmi, Petri, primary, Raki, Mari, primary, Laasonen, Leena, primary, Särkioja, Merja, primary, Rajecki, Maria, primary, Kangasniemi, Lotta, primary, Guse, Kilian, primary, Helminen, Andreas, primary, Ahtiainen, Laura, primary, Ristimäki, Ari, primary, Räisänen-Sokolowski, Anne, primary, Haavisto, Elina, primary, Oksanen, Minna, primary, Karli, Eerika, primary, Karioja-Kallio, Aila, primary, Holm, Sirkka-Liisa, primary, Kouri, Mauri, primary, Joensuu, Timo, primary, Kanerva, Anna, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure 1 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Pesonen, Sari, primary, Diaconu, Iulia, primary, Kangasniemi, Lotta, primary, Ranki, Tuuli, primary, Kanerva, Anna, primary, Pesonen, Saila K., primary, Gerdemann, Ulrike, primary, Leen, Ann M., primary, Kairemo, Kalevi, primary, Oksanen, Minna, primary, Haavisto, Elina, primary, Holm, Sirkka-Liisa, primary, Karioja-Kallio, Aila, primary, Kauppinen, Satu, primary, Partanen, Kaarina P. L., primary, Laasonen, Leena, primary, Joensuu, Tima, primary, Alanko, Tuomo, primary, Cerullo, Vincenzo, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure 4 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Pesonen, Sari, primary, Diaconu, Iulia, primary, Kangasniemi, Lotta, primary, Ranki, Tuuli, primary, Kanerva, Anna, primary, Pesonen, Saila K., primary, Gerdemann, Ulrike, primary, Leen, Ann M., primary, Kairemo, Kalevi, primary, Oksanen, Minna, primary, Haavisto, Elina, primary, Holm, Sirkka-Liisa, primary, Karioja-Kallio, Aila, primary, Kauppinen, Satu, primary, Partanen, Kaarina P. L., primary, Laasonen, Leena, primary, Joensuu, Tima, primary, Alanko, Tuomo, primary, Cerullo, Vincenzo, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

46. Human PSEN1 Mutant Glia Improve Spatial Learning and Memory in Aged Mice

Author

Jäntti, Henna, primary, Oksanen, Minna, additional, Kettunen, Pinja, additional, Manta, Stella, additional, Mouledous, Lionel, additional, Koivisto, Hennariikka, additional, Ruuth, Johanna, additional, Trontti, Kalevi, additional, Dhungana, Hiramani, additional, Keuters, Meike, additional, Weert, Isabelle, additional, Koskuvi, Marja, additional, Hovatta, Iiris, additional, Linden, Anni-Maija, additional, Rampon, Claire, additional, Malm, Tarja, additional, Tanila, Heikki, additional, Koistinaho, Jari, additional, and Rolova, Taisia, additional

Published
2022
Full Text
View/download PDF

48. Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus

Author

Cerullo, Vincenzo, Diaconu, Iulia, Kangasniemi, Lotta, Rajecki, Maria, Escutenaire, Sophie, Koski, Anniina, Romano, Valentina, Rouvinen, Noora, Tuuminen, Tamara, Laasonen, Leena, Partanen, Kaarina, Kauppinen, Satu, Joensuu, Timo, Oksanen, Minna, Holm, Sirkka-Liisa, Haavisto, Elina, Karioja-Kallio, Aila, Kanerva, Anna, Pesonen, Sari, Arstila, Petteri T, and Hemminki, Akseli

Published
2011
Full Text
View/download PDF

49. Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF

Author

Koski, Anniina, Kangasniemi, Lotta, Escutenaire, Sophie, Pesonen, Sari, Cerullo, Vincenzo, Diaconu, Iulia, Nokisalmi, Petri, Raki, Mari, Rajecki, Maria, Guse, Kilian, Ranki, Tuuli, Oksanen, Minna, Holm, Sirkka-Liisa, Haavisto, Elina, Karioja-Kallio, Aila, Laasonen, Leena, Partanen, Kaarina, Ugolini, Matteo, Helminen, Andreas, Karli, Eerika, Hannuksela, Päivi, Pesonen, Saila, Joensuu, Timo, Kanerva, Anna, and Hemminki, Akseli

Published
2010
Full Text
View/download PDF

50. Oncolytic adenovirus decreases the proportion of TIM-3+ subset of tumor-infiltrating CD8+ T cells with correlation to improved survival in patients with cancer

Author

Liikanen, Ilkka, primary, Basnet, Saru, additional, Quixabeira, Dafne C A, additional, Taipale, Kristian, additional, Hemminki, Otto, additional, Oksanen, Minna, additional, Kankainen, Matti, additional, Juhila, Juuso, additional, Kanerva, Anna, additional, Joensuu, Timo, additional, Tähtinen, Siri, additional, and Hemminki, Akseli, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results